Belatacept for prevention of acute rejection in adult patients who have had a kidney transplant: an update

References

• Meier-KriescheHUScholdJDSrinivasTRKaplanBLack of improvement in renal allograft survival despite a marked decrease in acute rejection rates over the most recent eraAm J Transplant20044337838314961990
   PubMed Web of Science ®Google Scholar
• United States Renal Data SystemUSRDS 2008 Annual Data Report: atlas of chronic kidney disease and end-stage renal disease in the United States Available from: http://www.usrds.org/adr.htmAccessed June 8, 2012
   Google Scholar
• JevnikarAMMannonRBLate kidney allograft loss: what we know about it, and what we can do about itClin J Am Soc Nephrol20083Suppl 2S56S6718309004
   PubMed Web of Science ®Google Scholar
• NankivellBJBorrowsRJFungCLO’ConnellPJAllenRDChapmanJRThe natural history of chronic allograft nephropathyN Engl J Med2003349242326233314668458
   PubMedGoogle Scholar
• AbramowiczDDel Carmen RialMVitkoSCyclosporine withdrawal from a mycophenolate mofetil-containing immunosuppressive regimen: results of a five-year, prospective, randomized studyJ Am Soc Nephrol20051672234224015917338
   PubMed Web of Science ®Google Scholar
• EkbergHTedesco-SilvaHDemirbasAReduced exposure to calcineurin inhibitors in renal transplantationN Engl J Med2007357252562257518094377
   PubMed Web of Science ®Google Scholar
• FlechnerSMGoldfarbDModlinCKidney transplantation without calcineurin inhibitor drugs: a prospective, randomized trial of sirolimus versus cyclosporineTransplantation20027481070107612438948
   PubMed Web of Science ®Google Scholar
• LarsonTSDeanPGStegallMDComplete avoidance of calcineurin inhibitors in renal transplantation: a randomized trial comparing sirolimus and tacrolimusAm J Transplant20066351452216468960
   PubMed Web of Science ®Google Scholar
• SchenaFPPascoeMDAlberuJConversion from calcineurin inhibitors to sirolimus maintenance therapy in renal allograft recipients: 24-month efficacy and safety results from the CONVERT trialTransplantation200987223324219155978
   PubMed Web of Science ®Google Scholar
• CosioFGGrandeJPWadeiHLarsonTSGriffinMDStegallMDPredicting subsequent decline in kidney allograft function from early surveillance biopsiesAm J Transplant20055102464247216162196
   PubMed Web of Science ®Google Scholar
• GastonRSCeckaJMKasiskeBLEvidence for antibody-mediated injury as a major determinant of late kidney allograft failureTransplantation2010901687420463643
   PubMed Web of Science ®Google Scholar
• GourishankarSLeducRConnettJPathological and clinical characterization of the ‘troubled transplant’: data from the DeKAF studyAm J Transplant201010232433020055809
   PubMed Web of Science ®Google Scholar
• HaririanAKiangkitiwanBKukurugaDThe impact of c4d pattern and donor-specific antibody on graft survival in recipients requiring indication renal allograft biopsyAm J Transplant20099122758276719845596
   PubMed Web of Science ®Google Scholar
• HidalgoLGCampbellPMSisBDe novo donor-specific antibody at the time of kidney transplant biopsy associates with microvascular pathology and late graft failureAm J Transplant20099112532254119843031
   PubMed Web of Science ®Google Scholar
• SisBJhangriGSBunnagSAllanachKKaplanBHalloranPFEndothelial gene expression in kidney transplants with alloantibody indicates antibody-mediated damage despite lack of C4d stainingAm J Transplant20099102312232319681822
   PubMed Web of Science ®Google Scholar
• LiXCRothsteinDMSayeghMHCostimulatory pathways in transplantation: challenges and new developmentsImmunol Rev2009229127129319426228
   PubMed Web of Science ®Google Scholar
• VincentiFCostimulation blockade in autoimmunity and transplantationJ Allergy Clin Immunol2008121229930618269922
   PubMed Web of Science ®Google Scholar
• LarsenCPPearsonTCAdamsABRational development of LEA29Y (belatacept), a high-affinity variant of CTLA4-Ig with potent immunosuppressive propertiesAm J Transplant20055344345315707398
   PubMed Web of Science ®Google Scholar
• LenschowDJZengYThistlethwaiteJRLong-term survival of xenogeneic pancreatic islet grafts induced by CTLA4lgScience199225750717897921323143
   PubMed Web of Science ®Google Scholar
• LatekRFleenerCLamianVAssessment of belatacept-mediated costimulation blockade through evaluation of CD80/86-receptor saturationTransplantation200987692693319300198
   PubMed Web of Science ®Google Scholar
• VincentiFLarsenCDurrbachACostimulation blockade with belatacept in renal transplantationN Engl J Med2005353877078116120857
   PubMed Web of Science ®Google Scholar
• VincentiFBlanchoGDurrbachAFive-year safety and efficacy of belatacept in renal transplantationJ Am Soc Nephrol20102191587159620634298
   PubMed Web of Science ®Google Scholar
• VincentiFCharpentierBVanrenterghemYA phase III study of belatacept-based immunosuppression regimens versus cyclosporine in renal transplant recipients (BENEFIT study)Am J Transplant201010353554620415897
   PubMed Web of Science ®Google Scholar
• LarsenCPGrinyoJMedina-PestanaJBelatacept-based regimens versus a cyclosporine A-based regimen in kidney transplant recipients: 2-year results from the BENEFIT and BENEFIT-EXT studiesTransplantation201090121528153521076381
   PubMed Web of Science ®Google Scholar
• VincentiFLarsenCPAlberuJThree-year outcomes from BENEFIT, a randomized, active-controlled, parallel-group study in adult kidney transplant recipientsAm J Transplant201212121021721992533
   PubMed Web of Science ®Google Scholar
• DurrbachAPestanaJMPearsonTA Phase III study of belatacept versus cyclosporine in kidney transplants from extended criteria donors (BENEFIT-EXT study)Am J Transplant201010354755720415898
   PubMed Web of Science ®Google Scholar
• PestanaJOGrinyoJMVanrenterghemYThree-year outcomes from BENEFIT-EXT: a Phase III study of belatacept versus cyclosporine in recipients of extended criteria donor kidneysAm J Transplant201212363063922300431
   PubMed Web of Science ®Google Scholar
• EverlyMJEverlyJJArendLJReducing de novo donor-specific antibody levels during acute rejection diminishes renal allograft lossAm J Transplant2009951063107119344434
   PubMed Web of Science ®Google Scholar
• OpelzGDohlerBInfluence of time of rejection on long-term graft survival in renal transplantationTransplantation200885566166618337655
   PubMed Web of Science ®Google Scholar
• RacusenLCColvinRBSolezKAntibody-mediated rejection criteria – an addition to the Banff 97 classification of renal allograft rejectionAm J Transplant20033670871412780562
   PubMed Web of Science ®Google Scholar
• TanakaTKyoMKokadoYCorrelation between the Banff 97 classification of renal allograft biopsies and clinical outcomeTranspl Int2004172596414551678
   PubMed Web of Science ®Google Scholar
• VereerstraetenPAbramowiczDde PauwLKinnaertPAbsence of deleterious effect on long-term kidney graft survival of rejection episodes with complete functional recoveryTransplantation19976312173917439210497
   PubMed Web of Science ®Google Scholar
• AdamsABPearsonTCLarsenCPHeterologous immunity: an overlooked barrier to toleranceImmunol Rev200319614716014617203
   PubMed Web of Science ®Google Scholar
• LakkisFGSayeghMHMemory T cells: a hurdle to immunologic toleranceJ Am Soc Nephrol20031492402241012937320
   PubMed Web of Science ®Google Scholar
• KitchensWHHaridasDWagenerMEIntegrin antagonists prevent costimulatory blockade-resistant transplant rejection by CD8(+) memory T cellsAm J Transplant2012121698021942986
   PubMed Web of Science ®Google Scholar
• AbramsJRLebwohlMGGuzzoCACTLA4Ig-mediated blockade of T-cell costimulation in patients with psoriasis vulgarisJ Clin Invest199910391243125210225967
   PubMed Web of Science ®Google Scholar
• BluestoneJALiuWYabuJMThe effect of costimulatory and interleukin 2 receptor blockade on regulatory T cells in renal transplantationAm J Transplant20088102086209618828769
   PubMed Web of Science ®Google Scholar
• GrinyoJCharpentierBPestanaJMAn integrated safety profile analysis of belatacept in kidney transplant recipientsTransplantation201090121521152721088650
   PubMed Web of Science ®Google Scholar
• Food and Drug AdministrationHighlights of prescribing information – Nulojix Available from: http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/125288s0000lbl.pdfAccessed June 8, 2012
   Google Scholar
• VanrenterghemYBresnahanBCampistolJBelatacept-based regimens are associated with improved cardiovascular and metabolic risk factors compared with cyclosporine in kidney transplant recipients (BENEFIT and BENEFIT-EXT studies)Transplantation201191997698321372756
   PubMed Web of Science ®Google Scholar
• DurrbachAPestanaJMPearstonTBelatacept vs cyclosporine in ECD kidney transplants: two-year outcomes from the BENEFIT-EXT studyAm J Transplant201010Suppl 4120089116
   PubMedGoogle Scholar
• GillJSTonelliMMixCHPereiraBJThe change in allograft function among long-term kidney transplant recipientsJ Am Soc Nephrol20031461636164212761266
   PubMed Web of Science ®Google Scholar
• OpelzGWujciakTRitzEAssociation of chronic kidney graft failure with recipient blood pressure. Collaborative Transplant StudyKidney Int19985312172229453022
   PubMed Web of Science ®Google Scholar
• MangeKCCizmanBJoffeMFeldmanHIArterial hypertension and renal allograft survivalJAMA2000283563363810665703
   PubMed Web of Science ®Google Scholar
• KasiskeBLAnjumSShahRHypertension after kidney transplantationAm J Kidney Dis20044361071108115168388
   PubMed Web of Science ®Google Scholar
• WissingKMAbramowiczDBroedersNVereerstraetenPHypercholesterolemia is associated with increased kidney graft loss caused by chronic rejection in male patients with previous acute rejectionTransplantation200070346447210949188
   PubMed Web of Science ®Google Scholar
• ColeEHJohnstonORoseCLGillJSImpact of acute rejection and new-onset diabetes on long-term transplant graft and patient survivalClin J Am Soc Nephrol20083381482118322046
   PubMed Web of Science ®Google Scholar
• CosioFGKudvaYvan der VeldeMNew onset hyperglycemia and diabetes are associated with increased cardiovascular risk after kidney transplantationKidney Int20056762415242115882287
   PubMed Web of Science ®Google Scholar
• KasiskeBLSnyderJJGilbertsonDMatasAJDiabetes mellitus after kidney transplantation in the United StatesAm J Transplant20033217818512603213
   PubMed Web of Science ®Google Scholar
• RostaingLNeumayerHHReyes-AcevedoRBelatacept-versus cyclosporine-based immunosuppression in renal transplant recipients with pre-existing diabetesClin J Am Soc Nephrol20116112696270421921152
   PubMed Web of Science ®Google Scholar